Evidence & transparency
Research library
We publish the science behind every compound — mechanism summaries, peer-reviewed references, and batch-specific Certificates of Analysis you can download and verify.
Certificates of Analysis
3 batchesIndependent HPLC / MS testing. Each row links to the full signed PDF.
| Product | Lot | Purity | Method | Date | COA |
|---|---|---|---|---|---|
| Retatrutide | BG4MA Vanguard Laboratory (ISO 17025) | 99.80% | HPLC-UV/VIS | 2026-02 | Download ↓ |
| Retatrutide | RET-260210-B1 Testides | 99.68% | HPLC-UV | 2026-02 | Download ↓ |
| KLOW Blend | M1-010120262028 Testides | 99.83% | HPLC-UV | 2026-02 | Download ↓ |
Clinical & mechanistic references
Retatrutide
Product →- 1.Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
- 2.Coskun T, et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metab. 2022.
KLOW Blend
Product →- 1.Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci. 2018.
- 2.Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 — research overview. Curr Pharm Des. 2018.